Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,386,030
  • Shares Outstanding, K 273,919
  • Annual Sales, $ 8,330 K
  • Annual Income, $ -89,300 K
  • EBIT $ -89 M
  • EBITDA $ -88 M
  • 60-Month Beta 1.06
  • Price/Sales 147.59
  • Price/Cash Flow N/A
  • Price/Book 5.59

Options Overview Details

View History
  • Implied Volatility 105.52% (-7.70%)
  • Historical Volatility 85.55%
  • IV Percentile 6%
  • IV Rank 4.51%
  • IV High 829.04% on 04/15/25
  • IV Low 71.32% on 08/20/25
  • Expected Move (DTE 14) 1.11 (21.88%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 469
  • Volume Avg (30-Day) 332
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 21,877
  • Open Int (30-Day) 26,231
  • Expected Range 3.95 to 6.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.09
  • Low Estimate -0.12
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.69 +36.75%
on 11/07/25
5.24 -3.63%
on 12/05/25
+1.02 (+25.31%)
since 11/05/25
3-Month
2.71 +86.31%
on 09/22/25
5.51 -8.32%
on 10/15/25
+1.69 (+50.30%)
since 09/05/25
52-Week
1.05 +380.95%
on 04/09/25
5.51 -8.32%
on 10/15/25
+2.67 (+112.18%)
since 12/05/24

Most Recent Stories

More News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 5.05 (-0.20%)
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which...

TSHA : 5.05 (-0.20%)
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 5.05 (-0.20%)
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic...

TSHA : 5.05 (-0.20%)
Citizens JMP Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

In a report released today, Silvan Tuerkcan from Citizens JMP reiterated a Buy rating on Taysha Gene Therapies, with a price target of $6.00. The company’s shares closed last Friday at $4.88.Elevate...

TSHA : 5.05 (-0.20%)
Truist Financial Remains a Buy on Taysha Gene Therapies (TSHA)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Taysha Gene Therapies. The company’s shares closed yesterday at $5.00.Elevate Your Investing Strategy: Take advantage...

TSHA : 5.05 (-0.20%)
Canaccord Genuity Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, with a price target of $14.00. The company’s shares closed yesterday at $5.00.Elevate...

TSHA : 5.05 (-0.20%)
Taysha Gene Therapies Presents Promising TSHA-102 Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Taysha Gene...

TSHA : 5.05 (-0.20%)
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced...

TSHA : 5.05 (-0.20%)
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Masimo (MASI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taysha Gene Therapies (TSHA – Research Report) and Masimo (MASI – Research Report) with bullish sentiments.Elevate...

MASI : 141.68 (-0.41%)
TSHA : 5.05 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104...

See More

Key Turning Points

3rd Resistance Point 5.43
2nd Resistance Point 5.33
1st Resistance Point 5.19
Last Price 5.05
1st Support Level 4.96
2nd Support Level 4.86
3rd Support Level 4.72

See More

52-Week High 5.51
Last Price 5.05
Fibonacci 61.8% 3.81
Fibonacci 50% 3.28
Fibonacci 38.2% 2.75
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar